PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2006-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00036218
- Locations
- 🇵🇷
Pfizer Investigational Site, Carolina, Puerto Rico
Chemoprevention of Oral Premalignant Lesions
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00036283
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9779
- Registration Number
- NCT00036270
- Locations
- 🇺🇸
Pfizer Investigational Site, Vancouver, Washington, United States
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-07
- Last Posted Date
- 2009-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT00035854
- Locations
- 🇺🇸
Research Center, Austin, Texas, United States
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 219
- Registration Number
- NCT00035347
- Locations
- 🇪🇸
Pfizer Investigational Site, Tarrasa, Cataluna, Spain
Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00035425
- Locations
Pfizer Investigational Site
A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2007-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 172
- Registration Number
- NCT00034827
- Locations
- 🇺🇸
Pfizer Investigational Site, Cincinnati, Ohio, United States
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2012-02-16
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00034957
- Locations
- 🇺🇸
Research Center, Dallas, Texas, United States
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 230
- Registration Number
- NCT00035269
- Locations
- 🇨🇳
Research Center, Taoyuan, Taiwan
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
- First Posted Date
- 2002-03-01
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00031278
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Fletcher Allen Health Care, Burlington, Vermont, United States
🇺🇸Univ. of Connecticut Health Center, Farmington, Connecticut, United States
© Copyright 2024. All Rights Reserved by MedPath